有关痛风、载脂蛋白B以及心血管疾病的研究进展
Research Progress on Gout, Apolipoprotein B and Cardiovascular Diseases
DOI: 10.12677/ACM.2021.119619, PDF,   
作者: 李 洁, 李海铭, 王忠超*：青岛大学附属医院内分泌与代谢性疾病科，山东 青岛；杨玉媛：青岛大学附属医院老年医学科，山东 青岛
关键词: 痛风；载脂蛋白B；心血管疾病；动脉粥样硬化；Gout； Apolipoprotein B； Cardiovascular Disease； Atherosclerosis
摘要: 痛风是内分泌常见的代谢紊乱性疾病之一，近些年来痛风的患病率逐年增加，而且易合并脂蛋白代谢异常，增加了痛风患者罹患心脑血管疾病的风险，不利于痛风患者的生活质量；同时脂蛋白代谢异常也是痛风发作及罹患心脑血管疾病的危险因素，三者之间相互关联。近来研究发现，痛风患者可伴有载脂蛋白B的异常，其在心血管疾病风险预测的作用优于低密度脂蛋白。现通过对文献收集整理，对痛风、载脂蛋白B以及心血管疾病的关系进行综述。
Abstract: Gout is one of the common endocrine metabolic disorders. In recent years, the prevalence of gout has increased year by year, and it is easy to be associated with abnormal lipoprotein metabolism, which increases the risk of gout in patients suffering from cardiovascular and cerebrovascular diseases, and is not conducive to the quality of life of gout patients. At the same time, abnormal lipoprotein metabolism is also a risk factor for gout attack and cardiovascular and cerebrovascular diseases, and the three are interrelated. Recent studies have found that patients with gout are associated with abnormal apolipoprotein B, which is better than LDL in predicting cardiovascular disease risk. This paper reviews the relationship between gout, apolipoprotein B and cardiovascular disease.
文章引用：李洁, 杨玉媛, 李海铭, 王忠超. 有关痛风、载脂蛋白B以及心血管疾病的研究进展[J]. 临床医学进展, 2021, 11(9): 4231-4235. https://doi.org/10.12677/ACM.2021.119619

参考文献

[1] Wu, M., Tian, Y., Wang, Q. and Guo, C. (2020) Gout: A Disease Involved with Complicated Immunoinflammatory Responses: A Narrative Review. Clinical Rheumatology, 39, 2849-2859. [Google Scholar] [CrossRef] [PubMed]
[2] Luk, A.J. and Simkin, P.A. (2005) Epidemiology of Hyperuricemia and Gout. The American Journal of Managed Care, 11, S435-S442; quiz S65-S68.
[3] Mackenzie, I.S., Ford, I., Nuki, G., Hallas, J., Hawkey, C.J., Webster, J., et al. (2020) Long-Term Cardiovascular Safety of Febuxostat Compared with Allopurinol in Patients with Gout (FAST): A Multicentre, Prospective, Randomised, Open-Label, Non-Inferiority Trial. Lancet, 396, 1745-1757. [Google Scholar] [CrossRef] 
[4] Sniderman, A.D., Thanassoulis, G., Glavinovic, T., Navar, A.M., Pencina, M., Catapano, A., et al. (2019) Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology, 4, 1287-1295. [Google Scholar] [CrossRef] [PubMed]
[5] Benn, M., Nordestgaard, B.G., Jensen, G.B. and Tybjaerg-Hansen, A. (2007) Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B: The Copenhagen City Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 661-670. [Google Scholar] [CrossRef] 
[6] Johannesen, C.D.L., Mortensen, M.B., Langsted, A. and Nordestgaard, B.G. (2021) Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology, 77, 1439-1450. [Google Scholar] [CrossRef] [PubMed]
[7] Kuo, C.F., Grainge, M.J., Zhang, W. and Doherty, M. (2015) Global Epidemiology of Gout: Prevalence, Incidence and Risk Factors. Nature Reviews Rheumatology, 11, 649-662. [Google Scholar] [CrossRef] [PubMed]
[8] Primatesta, P., Plana, E. and Rothenbacher, D. (2011) Gout Treatment and Comorbidities: A Retrospective Cohort Study in a Large US Managed Care Population. BMC Musculoskeletal Disorders, 12, Article No. 103. [Google Scholar] [CrossRef] [PubMed]
[9] Zheng, X., Gong, L., Luo, R., Chen, H., Peng, B., Ren, W., et al. (2017) Serum Uric Acid and Non-Alcoholic Fatty Liver Disease in Non-Obesity Chinese Adults. Lipids in Health and Disease, 16, Article No. 202. [Google Scholar] [CrossRef] [PubMed]
[10] Chen-Xu, M., Yokose, C., Rai, S.K., Pillinger, M.H. and Choi, H.K. (2019) Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis & Rheumatology, 71, 991-999. [Google Scholar] [CrossRef] [PubMed]
[11] Dehlin, M. and Jacobsson, L. (2020) Global Epidemiology of Gout: Prevalence, Incidence, Treatment Patterns and Risk Factors. Nature Reviews Rheumatology, 16, 380-390. [Google Scholar] [CrossRef] [PubMed]
[12] Safiri, S., Kolahi, A.A., Cross, M., Carson-Chahhoud, K., Hoy, D., Almasi-Hashiani, A., et al. (2020) Prevalence, Incidence, and Years Lived with Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017. Arthritis & Rheumatology, 72, 1916-1927. [Google Scholar] [CrossRef] [PubMed]
[13] Cohen, R.E. and Pillinger, M.H. (2020) Something Old, Something New: the ACR Gout Treatment Guideline and Its Evolution from 2012 to 2020. Current Rheumatology Reports, 23, Article No. 4. [Google Scholar] [CrossRef] [PubMed]
[14] Stamp, L.K. and Chapman, P.T. (2013) Gout and Its Comorbidities: Implications for Therapy. Rheumatology, 52, 34-44. [Google Scholar] [CrossRef] [PubMed]
[15] Takahashi, S., Yamamoto, T., Moriwaki, Y., Tsutsumi, Z. and Higashino, K. (1994) Impaired Lipoprotein Metabolism in Patients with Primary Gout—Influence of Alcohol Intake and Body Weight. British Journal of Rheumatology, 33, 731-734. [Google Scholar] [CrossRef] [PubMed]
[16] Rasheed, H., Hsu, A., Dalbeth, N., Stamp, L.K., McCormick, S. and Merriman, T.R. (2014) The Relationship of Apolipoprotein B and Very Low Density Lipoprotein Triglyceride with Hyperuricemia and Gout. Arthritis Research & Therapy, 16, Article No. 495. [Google Scholar] [CrossRef] [PubMed]
[17] Carr, S.S., Hooper, A.J., Sullivan, D.R. and Burnett, J.R. (2019) Non-HDL-Cholesterol and Apolipoprotein B Compared with LDL-Cholesterol in Atherosclerotic Cardiovascular Disease Risk Assessment. Pathology, 51, 148-154. [Google Scholar] [CrossRef] [PubMed]
[18] Jialal, I. (1996) A Practical Approach to the Laboratory Diagnosis of Dyslipidemia. American Journal of Clinical Pathology, 106, 128-138. [Google Scholar] [CrossRef] [PubMed]
[19] Goldstein, J.L. and Brown, M.S. (2015) A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell, 161, 161-172. [Google Scholar] [CrossRef] [PubMed]
[20] Skålén, K., Gustafsson, M., Rydberg, E.K., Hultén, L.M., Wiklund, O., Innerarity, T.L., et al. (2002) Subendothelial Retention of Atherogenic Lipoproteins in Early Atherosclerosis. Nature, 417, 750-754. [Google Scholar] [CrossRef] [PubMed]
[21] Libby, P., Loscalzo, J., Ridker, P.M., Farkouh, M.E., Hsue, P.Y., Fuster, V., et al. (2018) Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. Journal of the American College of Cardiology, 72, 2071-2081. [Google Scholar] [CrossRef] [PubMed]
[22] Welsh, C., Celis-Morales, C.A., Brown, R., Mackay, D.F., Lewsey, J., Mark, P.B., et al. (2019) Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation, 140, 542-552. [Google Scholar] [CrossRef] 
[23] Pencina, M.J., D’Agostino, R.B., Zdrojewski, T., Williams, K, Thanassoulis, G., Furberg, C.D., et al. (2015) Apolipoprotein B Improves Risk Assessment of Future Coronary Heart Disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. European Journal of Preventive Cardiology, 22, 1321-1327. [Google Scholar] [CrossRef] [PubMed]
[24] Wilkins, J.T., Li, R.C., Sniderman, A., Chan, C. and Lloyd-Jones, D.M. (2016) Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification: The CARDIA Study. Journal of the American College of Cardiology, 67, 193-201. [Google Scholar] [CrossRef] [PubMed]
[25] Meeusen, J.W., Donato, L.J. and Jaffe, A.S. (2016) Should Apolipoprotein B Replace LDL Cholesterol as Therapeutic Targets Are Lowered? Current Opinion in Lipidology, 27, 359-366. [Google Scholar] [CrossRef] 
[26] White, W.B., Saag, K.G., Becker, M.A., Borer, J.S., Gorelick, P.B., Whelton, A., et al. (2018) Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England Journal of Medicine, 378, 1200-1210. [Google Scholar] [CrossRef] 
[27] Thottam, G.E., Krasnokutsky, S. and Pillinger, M.H. (2017) Gout and Metabolic Syndrome: A Tangled Web. Current Rheumatology Reports, 19, Article No. 60. [Google Scholar] [CrossRef] [PubMed]
[28] Abbott, R.D., Brand, F.N., Kannel, W.B. and Castelli, W.P. (1988) Gout and Coronary Heart Disease: The Framingham Study. Journal of Clinical Epidemiology, 41, 237-242. [Google Scholar] [CrossRef] [PubMed]
[29] Edwards, N.L. (2009) The Role of Hyperuricemia in Vascular Disorders. Current Opinion in Rheumatology, 21, 132-137. [Google Scholar] [CrossRef] 
[30] Agabiti-Rosei, E. and Grassi, G. (2013) Beyond Gout: Uric Acid and Cardiovascular Diseases. Current Medical Research and Opinion, 29, 33-39. [Google Scholar] [CrossRef] [PubMed]
[31] Thanassoulis, G., Brophy, J.M., Richard, H. and Pilote, L. (2010) Gout, Allopurinol Use, and Heart Failure Outcomes. Archives of Internal Medicine, 170, 1358-1364. [Google Scholar] [CrossRef] [PubMed]
[32] Chen, J.H., Lan, J.L., Cheng, C.F., Liang, W.M., Lin, H.Y., Tsay, G.J., et al. (2015) Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study. PLoS ONE, 10, e0145193. [Google Scholar] [CrossRef] [PubMed]
[33] Chen, J.H., Lan, J.L., Cheng, C.F., Liang, W.M., Lin, H.Y., Tsay, G.J., et al. (2015) Effect of Urate-Lowering Therapy on the Risk of Cardiovascular Disease and All-Cause Mortality in Patients with Gout: A Case-Matched Cohort Study. The Journal of Rheumatology, 42, 1694-1701. [Google Scholar] [CrossRef] [PubMed]

为你推荐